The European Commission has approved elacestrant for the treatment of postmenopausal women and men with estrogen receptor–positive, HER2-negative, locally advanced, or metastatic breast cancer with an activating ESR1 mutation who have disease progression following at least 1 line of endocrine therapy including a CDK4/6 inhibitor.
Most specialists reached a consensus, although some may require more education on the clinical utility of breast cancer multigene signatures in early-stage disease, experts say.
Veracyte Announces New Consensus Data from PROCURE Study Presented at ESMO Breast Cancer 2022 - read this article along with other careers information, tips and advice on BioSpace